Press releases

To stay up to date with our development, sign up for a subscription.

Subscribe

Sedana Medical’s nomination committee appointed

Non-regulatory

Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 28, 2019, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…

Sedana Medical is co-funding AnaConDa study on lung protection

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is co-financing the world's largest multicenter study with AnaConDa in France. The primary purpose of the study is to show that inhaled sedation with AnaConDa has lung p…

Sedana Medical's AnaConDa approved to be used in children

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company's medical device AnaConDa, for the administration of volatile anesthetics for sedation of mechanically ventilated intensive care patients, has received approval for use…

Sedana Medical enters India – signs Indian distributor

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a distribution agreement with the Indian distributor Hansraj Nayyar Medical. Sales will commence in the fall and a registration process will start in parallel. Hansraj Nayyar has committ…

Sedana Medical enters China – signs with Chinese distributor

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a 10-year exclusive distribution agreement with the Chinese distributor Kyuan Xinhai Medical, a subsidiary of partly state-owned Shanghai Pharma, the second largest life science company…

Bulletin from annual general meeting in Sedana Medical AB (publ)

Regulatory

Sedana Medical AB (publ) (the "Company") held its annual general meeting on 28 May 2019 in Stockholm. The meeting resolved in accordance with all of the board of directors' and nomination committee's resolution proposals. Complete information on each…

Progress in Japan

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the first patient in Japan has been treated with AnaConDa and that the registration work for IsoConDa in Japan has been initiated. The Japanese market potential is estimated at EUR…

Sedana Medical publishes its Annual Report for 2018

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announce that its Annual Report for 2018 has been published and is available on www.sedanamedical.com under Investors.

Notice of Annual General Meeting in Sedana Medical AB (publ)

Regulatory

Sedana Medical AB (publ) hereby convenes the Annual General Meeting 2018. The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting on Tuesday 28 May 2019 at 4 p.m. (CEST) at Eri…

The road to registration in the US clarified

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the US Food and Drug Administration (FDA) during a pre-IND meeting is positive about the combination registration of IsoConDa and AnaConDa in the US. Sedana Medical now has a clear…

Positive interim analysis in pivotal IsoConDa phase III study

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the results of the interim analysis for the company's pivotal phase III study aimed at getting the candidate drug IsoConDa (isoflurane) approved for inhalation sedation in intensive care…

Sedana Medical establishes sedation research foundation

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the establishment of the Sedana Medical Research Foundation, creating a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill pati…